Company’s 36-month beta value is -3.17.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PHVS is 17.01M, and currently, short sellers hold a 1.08% ratio of that floaft. The average trading volume of PHVS on December 03, 2024 was 108.47K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PHVS) stock’s latest price update
The stock price of Pharvaris NV (NASDAQ: PHVS) has dropped by -12.56 compared to previous close of 21.90. Despite this, the company has seen a fall of -14.09% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business updates.
PHVS’s Market Performance
PHVS’s stock has fallen by -14.09% in the past week, with a monthly drop of -23.00% and a quarterly rise of 9.12%. The volatility ratio for the week is 13.00% while the volatility levels for the last 30 days are 8.22% for Pharvaris NV The simple moving average for the past 20 days is -12.08% for PHVS’s stock, with a -6.72% simple moving average for the past 200 days.
Analysts’ Opinion of PHVS
Many brokerage firms have already submitted their reports for PHVS stocks, with Wedbush repeating the rating for PHVS by listing it as a “Outperform.” The predicted price for PHVS in the upcoming period, according to Wedbush is $27 based on the research report published on September 25, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see PHVS reach a price target of $34, previously predicting the price at $10. The rating they have provided for PHVS stocks is “Overweight” according to the report published on August 15th, 2023.
Bryan Garnier gave a rating of “Buy” to PHVS, setting the target price at $16 in the report published on October 05th of the previous year.
PHVS Trading at -8.75% from the 50-Day Moving Average
After a stumble in the market that brought PHVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.97% of loss for the given period.
Volatility was left at 8.22%, however, over the last 30 days, the volatility rate increased by 13.00%, as shares sank -20.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.85% lower at present.
During the last 5 trading sessions, PHVS fell by -14.09%, which changed the moving average for the period of 200-days by -28.25% in comparison to the 20-day moving average, which settled at $21.78. In addition, Pharvaris NV saw -31.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHVS starting from MORGAN CONN, who proposed sale 26,562 shares at the price of $19.69 back on Dec 02 ’24. After this action, MORGAN CONN now owns shares of Pharvaris NV, valued at $522,937 using the latest closing price.
PENG LU, the Officer of Pharvaris NV, proposed sale 15,000 shares at $24.80 during a trade that took place back on Oct 31 ’24, which means that PENG LU is holding shares at $372,000 based on the most recent closing price.
Stock Fundamentals for PHVS
The total capital return value is set at -0.43. Equity return is now at value -58.16, with -54.26 for asset returns.
Currently, EBITDA for the company is -96.85 million with net debt to EBITDA at 2.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.08.
Conclusion
In a nutshell, Pharvaris NV (PHVS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
